Combination therapy for left-sided colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new experimental drug, EMB-01, combined with different chemotherapy regimens to treat left-sided colorectal cancer that has spread or cannot be removed. The goal is to see if this combination is safe and effective for people who have not responded to standard treatments or are new to certain chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 74 years old.
- Your colorectal cancer must be on the left side and cannot be removed by surgery or has spread to other parts of the body.
- You must be able to perform daily activities with minimal help (ECOG score 0 or 1).
- You need to provide a tumor sample (either from a previous biopsy or a new one) for testing.
- Depending on the treatment arm, you must have had certain prior chemotherapies or not, and your tumor must not have specific genetic changes (KRAS, NRAS, BRAF, or HER2).
- You must be willing to use effective birth control during treatment and for several months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
This trial compares two different chemotherapy combinations, each paired with an immunotherapy drug, as the first treatment for left-sided colorectal cancer that has spread. The goal is to see which combination works better and is safer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing three different combinations of existing and new drugs for advanced or metastatic colorectal cancer that hasn't improved with standard treatments or has spread to the liver. The goal is to see which combination works best and is safe for patients like you.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.